08 April 2020

Release of the Blue Paper by King & Wood Mallesons on Intellectual Property Protection - Comparative Study of Patent Linkage Systems in Different Countries and Discussion on Establishing Patent Linkage System in China

As China is growing from a pharmaceutical giant into a pharmaceutical power, since 2016, the CPC Central Committee and the State Council have issued a series of documents to clarify the intention of exploring the establishment of the drug patent linkage system. As an important institutional innovation in China's medical intellectual property protection, the drug patent linkage system provides balanced protection for both brand name drugs and generic drugs, thus creating a sound social ecology that protects innovation, encourages challenges, stimulates competition, sustains progress, and protects the health and well-being of the public.

Recently, the Supreme People's Court has included the issue of application of law concerning drug patent linkage disputes in the 2020 judicial interpretation project plan. The specific implementation of the drug patent linkage system has evoked extensive discussions from all walks of life. In particular, at the core of the implementation of such a system lies how to design a patent dispute resolution method in line with China's national conditions under such system.

The Blue Paper, with a total of nearly 70,000 Chinese characters, was completed in six months by a team of lawyers led by Tina Tai, partner of King & Wood Mallesons with rich patent experience in pharmaceutical chemistry, focusing on how to resolve patent disputes when establishing a patent linkage system in China. From the perspectives of historical development, implementation methods, policy orientation, market system and administrative and judicial systems, this Blue Paper proposes feasible patent dispute resolution methods in China based on China's national conditions and administrative and judicial practice by providing a detailed analysis and summary of generic drug approval and patent dispute resolution methods in various countries. It is hoped that this Blue Paper will contribute to the development of China's drug patent linkage system.

This Blue Paper is jointly released by King & Wood Mallesons and the KWM Institute.

Chinese version only


Share on LinkedIn Share on Facebook Share on Twitter
    You might also be interested in

    On April 21, 2020, Beijing Higher People’s Court released the Guidelines on Determination of Damages and Statutory Damages in Disputes over Intellectual Property and Unfair Competition (the ...

    28 May 2020

    As of May 1, 2020, parties making a voluntary notice filing with CFIUS will have to pay a filing fee. There is no fee for declarations under the mandatory filing regime. The Treasury Department’s...

    26 May 2020

    This article was first published in Foreign Investment Watch. According to a recent study conducted by an international law firm headquartered in Asia, Chinese deals have been &ldquo...

    26 May 2020

    On May 21, 2020, the United States Senate passed the Holding Foreign Companies Accountable Act (the “Bill”) with unanimous consent.

    25 May 2020

    This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

    For more information on which cookies we use then please refer to our Cookie Policy.